Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of chemoradiation plus adjuvant chemotherapy versus pelvic radiotherapy alone in high-risk endometrial carcinoma
ISRCTN14387080Phase 3Completed
- Sponsor
- Leiden University Medical Center
- Start
- Sep 2006
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of cisplatin, carboplatin and paclitaxel in endometrial cancer (EC) (2 arms), sponsored by Leiden University Medical Center. Primary endpoints: Five-year actuarial overall survival and Five-year actuarial failure-free survival. Started Sep 2006; status: completed.
02
Drugs
cisplatincarboplatinpaclitaxel
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on ISRCTN14387080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14387080.